Bachem Holding AG

Bachem Holding AG, founded in 1971 and headquartered in Bubendorf, Switzerland, is a pioneering and independent technology-based biochemical company providing full service to the pharma and biotech industry. Bachem is exclusively focused on peptides and oligonucleotides, standing as the undisputed global leader in this highly specialized niche.

The company has revolutionized the commercial synthesis of complex peptides, bringing decades of unparalleled expertise to both solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS). With a global footprint encompassing cutting-edge manufacturing facilities in Switzerland, the United States, and the United Kingdom, Bachem supports its partners seamlessly from early-stage clinical research through to commercial-scale production.

Bachem’s product portfolio includes an extensive catalog of research-grade biochemicals, but its core business lies in the custom development and manufacturing of Active Pharmaceutical Ingredients (APIs) under strict Good Manufacturing Practice (GMP) conditions. The organization is at the forefront of innovation in oligonucleotide synthesis, investing heavily in new technologies to meet the surging global demand for RNA-based therapeutics.

Bachem is recognized for its exceptional regulatory compliance, holding approvals from major global health authorities such as the US FDA, EMA, and PMDA. Beyond manufacturing, Bachem is deeply committed to scientific advancement, frequently publishing research on peptide chemistry, purification techniques, and sustainable manufacturing processes.

Their capabilities are considered world-class, making them the partner of choice for pharmaceutical companies developing next-generation targeted therapies. Driven by a culture of precision and Swiss quality, Bachem continues to set the industry standard for complex molecule synthesis, playing a critical role in bringing innovative treatments for cancer, metabolic disorders, and rare diseases to patients worldwide.